Phase 3 N=680 Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Trauma
Primary: 24-hour Mortality — 43; 58 participants — p=0.12
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=504 Protecta Smart Analysis Register
Patients With an Indication for an ICD Implantation According to the Guidelines
Primary: Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology. — 94.9 % of episodes wo shock due to SmartShock
N/A N=1,457 PROPPER Prospective Registry of Outcomes With Penile Prosthesis
Erectile Dysfunction · Impotence
Primary: Number of Participants With Penile Prosthesis Overall Subject Satisfaction — 34; 34; 0; 0 Participants
Phase 2 N=21 Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
Pregnancy Complications
Primary: Number of Participants With Achievement of 34 Weeks Gestation — 0; 0 Participants
N/A N=5 PraxbindTM India PMS Program
Thromboembolism
Primary: Number of Participants With Suspected Adverse Drug Reactions (ADRs) and Fatal Adverse Events (AEs) — 0; 0 Participants
N/A N=53 Pivotal Response Group Treatment for Parents of Young Children With Autism
Autistic Disorder
Primary: Change From Baseline in Communication During Structured Lab Observation (SLO) at 12 Weeks — 45.7; 40.8; 64.5; 51.4 Utterances — p=0.42
N/A N=897 PREFER (Pacemaker Remote Follow-Up Evaluation and Review)
Bradycardia · Arrhythmia
Primary: Percentage of Participants With First Diagnosis of Clinically Actionable Events (CAE) at 12 Months — 35; 47 Percentage of participants — p=<0.0001
N/A N=36 The Prefyx PPS™ System eRegistry
Stress Urinary Incontinence
Primary: Number of Participants Who Remain Continent or Improved Following Treatment Through 3 Months Follow-up — 26 Participants
N/A N=50,458 Primary Palliative Care for Emergency Medicine (PRIM-ER)
Emergencies
Primary: Acute Care Admission — 0.644; 0.613 Proportion of participants
Phase 3 N=66 A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
Central Precocious Puberty
Primary: Percentage of Participants With Luteinising Hormone (LH) Suppression — 100 percentage of participants
N/A N=870 Physiologic Pacing Registry
Bradycardia · Sinus Node Dysfunction · Heart Block
Primary: Physiologic Pacing Implant Success Rate — 768 Participants
Phase 3 N=156 PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
ADHD
Primary: Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom — 11.4; 18.2 score on SKAMP-C — p=<0.0001
Phase 2 N=108 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
Proliferative Diabetic Retinopathy (PDR)
Primary: Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS) — -4.6; -0.9; -1.7 square millimeters — p=0.0344
N/A N=2,103 The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization
Coronary Artery Disease
Primary: Primary Composite (Number) of Deaths / MIs / Invasive Coronary Angiography Without Obstructive Disease — 44; 118; 18; 12 number of events — p=<.001
N/A N=141 Program Reinforcement Impacts Self Management (PRISM)
Diabetes Mellitus
Primary: Hemoglobin A1C (HbA1C, %) — 6.8; 7.6; 6.8; 7.1 percentage of glycosolated hemoglobin
N/A N=10 Pain Rehabilitation Virtual Reality (PRVR): Innovations to Enhance Mobility in the Presence of Pain
Chronic Pain · Musculoskeletal Pain · Fibromyalgia
Primary: VR Duration of Use Per Week — 30.5; 17.0 Minutes per week
N/A N=31 Assess the Effectiveness of Pulse RadioFrequency in Patients With Chronic Lumbar Radicular Pain
Chronic Pain · Back Pain
Primary: Recruitment Rate — 32 Participants
N/A N=246 P3 (Prepared, Protected, emPowered)
Sexually Transmitted Diseases · Safe Sex · Adherence, Medication
Primary: PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) — 24; 33; 23; 18 Participants — p=0.04965
Phase 3 N=375 The Efficacy and Safety of PRC-063 in Adult ADHD Patients
ADHD
Primary: Change From Baseline in Clinician-administered ADHD-5-Rating Scale Total Score — 24.2; 19.9; 24.0; 18.7 units on a scale — p=0.6750
Phase 3 N=344 A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
Parkinson Disease
Primary: Mean Change From Baseline in Total Awake Time Spent "Off" at Week 24 Using Last Observation Carried Forward (LOCF) — -0.4; -2.1 hours — p=<0.001
Phase 3 N=689 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 54 for the Study Eye — 0.2; -4.2 Letters Read — p=<0.001
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
N/A N=3,004 Pragmatic Airway Resuscitation Trial
Cardiac Arrest
Primary: Number of Patients Alive at 72 Hours After Episode. — 230; 275 Participants
N/A N=175 Preemie Prep For Parents (P3): Home Antenatal Prematurity Education
Premature Birth · Decision Making · Prenatal Care
Primary: Parent Prematurity Knowledge Questionnaire — 30.3; 22.8; 29.3; 25.6 score on a scale
N/A N=18,693 Paediatric Rapid Sepsis Trigger (PRST) Tool
Sepsis · Infection
Primary: Time to Administration of an Appropriate Antimicrobial — 115; 123; 239; 261 minutes
N/A N=751 Protocolized Post-Extubation Respiratory Support Study
Mechanical Ventilation Complication · Acute Respiratory Failure · Intubation Complication
Primary: Reintubation — 57; 52 Participants
Phase 2 N=14 Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI
N/A N=960 PrEPARE: PrEP in Pregnancy, Accelerating Reach and Efficiency
Pre-Exposure Prophylaxis · HIV Infections · Pregnancy Related
Primary: PrEP Penetration — 30; 17; 46; 8 Participants
N/A N=106 Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP
HIV-1-infection
Primary: Recent PrEP Adherence — 33; 18 Participants — p=<0.001
N/A N=42 Practice Experiences for School Reintegration
Suicide
Primary: Proportion of Patients in the Target Population Who Agree to Participate — 0.384 proportion of potential participants